A Randomized Dose-ranging Controlled Trial of DU-176b Versus Warfarin Potassium in Patients With Non-valvular Atrial Fibrillation
Latest Information Update: 09 Nov 2021
At a glance
- Drugs Edoxaban (Primary) ; Warfarin
- Indications Cerebral infarction; Embolism; Stroke; Thromboembolism; Thrombosis
- Focus Adverse reactions
- Sponsors Daiichi Sankyo Company
- 15 Jul 2009 Results were presented at the 22nd Congress of the International Society on Thrombosis and Haemostasis.
- 31 Jan 2009 New trial record